

Federica Bozzano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5679387/publications.pdf>

Version: 2024-02-01

30
papers

1,000
citations

586496

16
h-index

563245

28
g-index

31
all docs

31
docs citations

31
times ranked

2347
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 847816.	2.2	2
2	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab217.	0.4	64
3	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021, 17, e1009448.	2.1	43
4	HCMV-controlling NKG2C+ NK cells originate from novel circulating inflammatory precursors. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2343-2357.	1.5	16
5	A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication. <i>Journal of Translational Medicine</i> , 2020, 18, 204.	1.8	7
6	Human NK Cells and Herpesviruses: Mechanisms of Recognition, Response and Adaptation. <i>Frontiers in Microbiology</i> , 2019, 10, 2297.	1.5	32
7	NK Cell Precursors in Human Bone Marrow in Health and Inflammation. <i>Frontiers in Immunology</i> , 2019, 10, 2045.	2.2	8
8	Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naïve HCV patients: The type of DAA matters. <i>Immunology Letters</i> , 2018, 203, 112-115.	1.1	0
9	Analysis of NK Cell Function and Receptor Expression During HTLV-1 and HTLV-2 Infection. <i>Methods in Molecular Biology</i> , 2017, 1582, 183-194.	0.4	0
10	Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. <i>Journal of Virology</i> , 2017, 91, .	1.5	39
11	Natural Killer Cell Development and Maturation Revisited: Possible Implications of a Novel Distinct Lin ⁺ CD34+DNAM-1brightCXCR4+ Cell Progenitor. <i>Frontiers in Immunology</i> , 2017, 8, 268.	2.2	16
12	Emergency exit of bone-marrow-resident CD34+DNAM-1brightCXCR4+-committed lymphoid precursors during chronic infection and inflammation. <i>Nature Communications</i> , 2015, 6, 8109.	5.8	22
13	Inherent transcriptional signatures of NK cells are associated with response to IFN-α/β+sofosbuvir therapy in patients with Hepatitis C Virus. <i>Journal of Translational Medicine</i> , 2015, 13, 77.	1.8	8
14	IMMUNOLOGY OF TUBERCULOSIS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014027.	0.5	53
15	Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. <i>Frontiers in Immunology</i> , 2014, 5, 305.	2.2	16
16	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA <50 cp/mL. <i>Journal of the International AIDS Society</i> , 2014, 17, 19718.	1.2	2
17	Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients. <i>Aids</i> , 2014, 28, 1071-1074.	1.0	5
18	Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	32

#	ARTICLE	IF	CITATIONS
19	Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11970-11975.	3.3	73
20	HTLV-1/2 and HIV-1 co-infections: retroviral interference on host immune status. <i>Frontiers in Microbiology</i> , 2013, 4, 372.	1.5	29
21	The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials. <i>Medicine</i> 2013, 2, e5.	2.4	22
22	Natural killer cells in hepatitis C virus infection. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 775-788.	1.3	9
23	Receptor modulation and functional activation of human CD34 ⁺ HLA ⁻ derived immature NK cells in vitro by <i>Mycobacterium bovis</i> BCG/acillus C ^{almette} G ^{uerin} (BCG). <i>European Journal of Immunology</i> , 2012, 42, 2459-2470.	1.6	5
24	Activating NK cell receptor expression/function (NKp30, NKp46, DNAM1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. <i>European Journal of Immunology</i> , 2011, 41, 2905-2914.	1.6	66
25	Revisiting human natural killer cell subset function revealed cytolytic CD56 ^{dim} CD16 ⁺ NK cells as rapid producers of abundant IFN- γ on activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 728-732.	3.3	306
26	NK-cell phenotype at interruption underlies widely divergent duration of CD4 ⁺ -guided antiretroviral treatment interruption. <i>International Immunology</i> , 2011, 23, 109-118.	1.8	14
27	Involvement of Activating NK Cell Receptors and Their Modulation in Pathogen Immunity. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-11.	3.0	38
28	Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. <i>International Immunology</i> , 2009, 21, 779-791.	1.8	61
29	IFN- γ -mediated increase in cytolytic activity of maturing NK cell upon exposure to HSV-infected myelomonocytes. <i>European Journal of Immunology</i> , 2009, 39, 147-158.	1.6	11
30	Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. <i>Clinical and Experimental Immunology</i> , 2009, 158, 55-63.	1.1	1